Thermogenesis is a medical devices business based in the US. Thermogenesis shares (THMO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.18 – an increase of 2.88% over the previous week. Thermogenesis employs 25 staff and has a trailing 12-month revenue of around $9.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.18 |
|---|---|
| 52-week range | $0.10 - $1.25 |
| 50-day moving average | $0.20 |
| 200-day moving average | $0.50 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.98 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.175 from 2024-10-07
| 1 week (2024-10-01) | 2.88% |
|---|---|
| 1 month (2024-09-06) | -30.00% |
| 3 months (2024-07-08) | 8.02% |
| 6 months (2024-04-08) | -79.08% |
| 1 year (2023-10-06) | -85.04% |
|---|---|
| 2 years (2022-10-07) | -35.19% |
| 3 years (2021-10-08) | 1.81 |
| 5 years (2019-10-08) | 6.13 |
| Revenue TTM | $9.6 million |
|---|---|
| Gross profit TTM | $3.5 million |
| Return on assets TTM | -25.5% |
| Return on equity TTM | -801.94% |
| Profit margin | -153.43% |
| Book value | $0.12 |
| Market Capitalization | $2.7 million |
TTM: trailing 12 months
We're not expecting Thermogenesis to pay a dividend over the next 12 months.
Thermogenesis's shares were split on a 1:45 basis on 21 December 2022. So if you had owned 45 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Thermogenesis shares – just the quantity. However, indirectly, the new 4400% higher share price could have impacted the market appetite for Thermogenesis shares which in turn could have impacted Thermogenesis's share price.
Over the last 12 months, Thermogenesis's shares have ranged in value from as little as $0.1 up to $1.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Thermogenesis's is 2.304. This would suggest that Thermogenesis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.